Present status and perspectives of colorectal cancer in Asia: Colorectal cancer working group report in 30th Asia-Pacific cancer conference

Ichinosuke Hyodo, Hideo Suzuki, Keiichi Takahashi, Yoko Saito, Shinji Tanaka, Han Mo Chiu, Nam Kyu Kim, Jin Li, Robert Lim, Antonio Villalon, Narikazu Boku

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: To reveal the present status and future directions of colorectal cancer in Asia. Methods: The Working Group consisted of oncologists from six Asian countries (Japan, Korea, Hong Kong, China, Taiwan, Singapore and Philippines) discussed colorectal cancer in the 30th Asia-Pacific Cancer Conference and made a consensus report. Results: The incidence of colorectal cancer has been increasing rapidly in recent decades, and mortality has also increased except in Japan and Singapore. Colorectal screening with fecal occult blood tests is a national policy in Taiwan, Japan and Korea. Total colonoscopy is the most common examination for diagnosing colorectal cancers and neoplasms. However, there are differences in the macroscopic classification used. Laparoscopic surgery for colon cancer is extensively used, although the indication varies. Adequate lymph node harvesting of more than 12 nodes is performed in most countries. Neoadjuvant chemoradiation therapy is not routinely done for T2 or T3 rectal cancer. Total mesorectal excision is the standard surgery for rectal cancer. Survival rate data are unavailable for many countries and should be compiled in all. The differences in the health-care delivery systems affect the treatment choices for unresectable colorectal cancer. Infusional 5-FU plus leucovorin plus oxaliplatin (FOLFOX) is the most popular first-line regimen. Cetuximab is mainly used as a second- or third-line regimen with reference to k-ras mutation. Oxaliplatin-based adjuvant chemotherapy is commonly used for stage III disease, whereas the clinical practice for stage II disease varies. Conclusions: Further clinical cooperation is needed to optimize the management of colorectal cancer in Asia.

Original languageEnglish
Article numberhyq125
Pages (from-to)i38-i43
JournalJapanese Journal of Clinical Oncology
Volume40
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Colorectal Neoplasms
oxaliplatin
Neoplasms
Japan
Singapore
Rectal Neoplasms
Korea
Taiwan
Delivery of Health Care
Occult Blood
Neoadjuvant Therapy
Philippines
Leucovorin
Hematologic Tests
Hong Kong
Colonoscopy
Adjuvant Chemotherapy
Fluorouracil
Laparoscopy
Colonic Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Hyodo, Ichinosuke ; Suzuki, Hideo ; Takahashi, Keiichi ; Saito, Yoko ; Tanaka, Shinji ; Chiu, Han Mo ; Kim, Nam Kyu ; Li, Jin ; Lim, Robert ; Villalon, Antonio ; Boku, Narikazu. / Present status and perspectives of colorectal cancer in Asia : Colorectal cancer working group report in 30th Asia-Pacific cancer conference. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. SUPPL. 1. pp. i38-i43.
@article{0ab2d383301d4e769a655f2bb2047987,
title = "Present status and perspectives of colorectal cancer in Asia: Colorectal cancer working group report in 30th Asia-Pacific cancer conference",
abstract = "Objective: To reveal the present status and future directions of colorectal cancer in Asia. Methods: The Working Group consisted of oncologists from six Asian countries (Japan, Korea, Hong Kong, China, Taiwan, Singapore and Philippines) discussed colorectal cancer in the 30th Asia-Pacific Cancer Conference and made a consensus report. Results: The incidence of colorectal cancer has been increasing rapidly in recent decades, and mortality has also increased except in Japan and Singapore. Colorectal screening with fecal occult blood tests is a national policy in Taiwan, Japan and Korea. Total colonoscopy is the most common examination for diagnosing colorectal cancers and neoplasms. However, there are differences in the macroscopic classification used. Laparoscopic surgery for colon cancer is extensively used, although the indication varies. Adequate lymph node harvesting of more than 12 nodes is performed in most countries. Neoadjuvant chemoradiation therapy is not routinely done for T2 or T3 rectal cancer. Total mesorectal excision is the standard surgery for rectal cancer. Survival rate data are unavailable for many countries and should be compiled in all. The differences in the health-care delivery systems affect the treatment choices for unresectable colorectal cancer. Infusional 5-FU plus leucovorin plus oxaliplatin (FOLFOX) is the most popular first-line regimen. Cetuximab is mainly used as a second- or third-line regimen with reference to k-ras mutation. Oxaliplatin-based adjuvant chemotherapy is commonly used for stage III disease, whereas the clinical practice for stage II disease varies. Conclusions: Further clinical cooperation is needed to optimize the management of colorectal cancer in Asia.",
author = "Ichinosuke Hyodo and Hideo Suzuki and Keiichi Takahashi and Yoko Saito and Shinji Tanaka and Chiu, {Han Mo} and Kim, {Nam Kyu} and Jin Li and Robert Lim and Antonio Villalon and Narikazu Boku",
year = "2010",
month = "9",
day = "1",
doi = "10.1093/jjco/hyq125",
language = "English",
volume = "40",
pages = "i38--i43",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

Hyodo, I, Suzuki, H, Takahashi, K, Saito, Y, Tanaka, S, Chiu, HM, Kim, NK, Li, J, Lim, R, Villalon, A & Boku, N 2010, 'Present status and perspectives of colorectal cancer in Asia: Colorectal cancer working group report in 30th Asia-Pacific cancer conference', Japanese Journal of Clinical Oncology, vol. 40, no. SUPPL. 1, hyq125, pp. i38-i43. https://doi.org/10.1093/jjco/hyq125

Present status and perspectives of colorectal cancer in Asia : Colorectal cancer working group report in 30th Asia-Pacific cancer conference. / Hyodo, Ichinosuke; Suzuki, Hideo; Takahashi, Keiichi; Saito, Yoko; Tanaka, Shinji; Chiu, Han Mo; Kim, Nam Kyu; Li, Jin; Lim, Robert; Villalon, Antonio; Boku, Narikazu.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. SUPPL. 1, hyq125, 01.09.2010, p. i38-i43.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Present status and perspectives of colorectal cancer in Asia

T2 - Colorectal cancer working group report in 30th Asia-Pacific cancer conference

AU - Hyodo, Ichinosuke

AU - Suzuki, Hideo

AU - Takahashi, Keiichi

AU - Saito, Yoko

AU - Tanaka, Shinji

AU - Chiu, Han Mo

AU - Kim, Nam Kyu

AU - Li, Jin

AU - Lim, Robert

AU - Villalon, Antonio

AU - Boku, Narikazu

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objective: To reveal the present status and future directions of colorectal cancer in Asia. Methods: The Working Group consisted of oncologists from six Asian countries (Japan, Korea, Hong Kong, China, Taiwan, Singapore and Philippines) discussed colorectal cancer in the 30th Asia-Pacific Cancer Conference and made a consensus report. Results: The incidence of colorectal cancer has been increasing rapidly in recent decades, and mortality has also increased except in Japan and Singapore. Colorectal screening with fecal occult blood tests is a national policy in Taiwan, Japan and Korea. Total colonoscopy is the most common examination for diagnosing colorectal cancers and neoplasms. However, there are differences in the macroscopic classification used. Laparoscopic surgery for colon cancer is extensively used, although the indication varies. Adequate lymph node harvesting of more than 12 nodes is performed in most countries. Neoadjuvant chemoradiation therapy is not routinely done for T2 or T3 rectal cancer. Total mesorectal excision is the standard surgery for rectal cancer. Survival rate data are unavailable for many countries and should be compiled in all. The differences in the health-care delivery systems affect the treatment choices for unresectable colorectal cancer. Infusional 5-FU plus leucovorin plus oxaliplatin (FOLFOX) is the most popular first-line regimen. Cetuximab is mainly used as a second- or third-line regimen with reference to k-ras mutation. Oxaliplatin-based adjuvant chemotherapy is commonly used for stage III disease, whereas the clinical practice for stage II disease varies. Conclusions: Further clinical cooperation is needed to optimize the management of colorectal cancer in Asia.

AB - Objective: To reveal the present status and future directions of colorectal cancer in Asia. Methods: The Working Group consisted of oncologists from six Asian countries (Japan, Korea, Hong Kong, China, Taiwan, Singapore and Philippines) discussed colorectal cancer in the 30th Asia-Pacific Cancer Conference and made a consensus report. Results: The incidence of colorectal cancer has been increasing rapidly in recent decades, and mortality has also increased except in Japan and Singapore. Colorectal screening with fecal occult blood tests is a national policy in Taiwan, Japan and Korea. Total colonoscopy is the most common examination for diagnosing colorectal cancers and neoplasms. However, there are differences in the macroscopic classification used. Laparoscopic surgery for colon cancer is extensively used, although the indication varies. Adequate lymph node harvesting of more than 12 nodes is performed in most countries. Neoadjuvant chemoradiation therapy is not routinely done for T2 or T3 rectal cancer. Total mesorectal excision is the standard surgery for rectal cancer. Survival rate data are unavailable for many countries and should be compiled in all. The differences in the health-care delivery systems affect the treatment choices for unresectable colorectal cancer. Infusional 5-FU plus leucovorin plus oxaliplatin (FOLFOX) is the most popular first-line regimen. Cetuximab is mainly used as a second- or third-line regimen with reference to k-ras mutation. Oxaliplatin-based adjuvant chemotherapy is commonly used for stage III disease, whereas the clinical practice for stage II disease varies. Conclusions: Further clinical cooperation is needed to optimize the management of colorectal cancer in Asia.

UR - http://www.scopus.com/inward/record.url?scp=77957275712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957275712&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq125

DO - 10.1093/jjco/hyq125

M3 - Article

C2 - 20870918

AN - SCOPUS:77957275712

VL - 40

SP - i38-i43

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - SUPPL. 1

M1 - hyq125

ER -